WO2006034356A3 - Cardiac pressure overload associated genes - Google Patents

Cardiac pressure overload associated genes Download PDF

Info

Publication number
WO2006034356A3
WO2006034356A3 PCT/US2005/033853 US2005033853W WO2006034356A3 WO 2006034356 A3 WO2006034356 A3 WO 2006034356A3 US 2005033853 W US2005033853 W US 2005033853W WO 2006034356 A3 WO2006034356 A3 WO 2006034356A3
Authority
WO
WIPO (PCT)
Prior art keywords
heart
methods
pressure overload
failure
heart failure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/033853
Other languages
French (fr)
Other versions
WO2006034356A9 (en
WO2006034356A2 (en
Inventor
Roger A Wagner
Raymond Tabibiazar
Thomas Quertermous
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Priority to EP05806752A priority Critical patent/EP1797199A2/en
Priority to CA002580191A priority patent/CA2580191A1/en
Priority to JP2007532650A priority patent/JP2008515394A/en
Publication of WO2006034356A2 publication Critical patent/WO2006034356A2/en
Publication of WO2006034356A9 publication Critical patent/WO2006034356A9/en
Anticipated expiration legal-status Critical
Publication of WO2006034356A3 publication Critical patent/WO2006034356A3/en
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention identifies genes whose gene products are differentially expressed pressure overload of the heart. The invention provides methods for diagnosing or assessing an individual's susceptibility to heart failure from many etiologies, as well as the presence and severity of hypertrophy, chamber enlargement, or systolic heat failure. Also provided are therapeutic methods for treating a heart patient or methods for prophylactically treating an individual susceptible to heart failure. Additionally, the invention describes screening methods for identifying agents that can be administered to treat individuals that have suffered a heart attack or are at risk of heart failure.
PCT/US2005/033853 2004-09-20 2005-09-20 Cardiac pressure overload associated genes Ceased WO2006034356A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP05806752A EP1797199A2 (en) 2004-09-20 2005-09-20 Cardiac pressure overload associated genes
CA002580191A CA2580191A1 (en) 2004-09-20 2005-09-20 Cardiac pressure overload associated genes
JP2007532650A JP2008515394A (en) 2004-09-20 2005-09-20 Heart pressure related genes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61167404P 2004-09-20 2004-09-20
US60/611,674 2004-09-20

Publications (3)

Publication Number Publication Date
WO2006034356A2 WO2006034356A2 (en) 2006-03-30
WO2006034356A9 WO2006034356A9 (en) 2006-06-22
WO2006034356A3 true WO2006034356A3 (en) 2009-04-16

Family

ID=36090655

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/033853 Ceased WO2006034356A2 (en) 2004-09-20 2005-09-20 Cardiac pressure overload associated genes

Country Status (5)

Country Link
US (1) US20060094038A1 (en)
EP (1) EP1797199A2 (en)
JP (1) JP2008515394A (en)
CA (1) CA2580191A1 (en)
WO (1) WO2006034356A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8691587B2 (en) 2008-04-30 2014-04-08 Roche Diagnostics Operations, Inc. Use of SFRP-3 in the assessment of heart failure

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006102497A2 (en) * 2005-03-22 2006-09-28 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for diagnosis, monitoring and development of therapeutics for treatment of atherosclerotic disease
US9670244B2 (en) 2006-02-27 2017-06-06 The Regents Of The University Of California Oxysterol compounds and the hedgehog pathway
WO2007146187A2 (en) * 2006-06-06 2007-12-21 Reika Ortho Technologies, Inc. Transduction orthodontic devices
US8153376B2 (en) 2006-09-25 2012-04-10 Universiteit Maastricht Means and methods for diagnosing and/or treating a subject at risk of developing heart failure
WO2008107201A1 (en) 2007-03-08 2008-09-12 Roche Diagnostics Gmbh Use of slim-1 in the assessment of heart failure
AU2008247649A1 (en) 2007-05-01 2008-11-13 University Of Miami Transcriptomic biomarkers for individual risk assessment in new onset heart failure
WO2009059115A1 (en) * 2007-10-31 2009-05-07 Trustees Of The University Of Pennsylvania Culture based screening assay and methods of use thereof to identify agents which modulate tumor development, invasion and differentiation
CA2738417A1 (en) * 2008-10-17 2010-04-22 F. Hoffmann-La Roche Ag Use of biglycan in the assessment of heart failure
US20120142544A1 (en) 2009-06-02 2012-06-07 University Of Miami Diagnostic transcriptomic biomarkers in inflammatory cardiomyopathies
WO2011033034A1 (en) * 2009-09-17 2011-03-24 Roche Diagnostics Gmbh Multimarker panel for left ventricular hypertrophy
AU2010309808B2 (en) * 2009-10-21 2016-04-28 Mycartis Nv Biomarker for diagnosis, prediction and/or prognosis of acute heart failure and uses thereof
CN102135542A (en) * 2010-01-21 2011-07-27 北京大学 ELISA (Enzyme Linked Immunosorbent Assay) method and kit for detecting soluble protein PDCD5 (Programmed Cell Death 5)
US9539427B2 (en) 2010-11-08 2017-01-10 The Johns Hopkins University Methods for improving heart function

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050152836A1 (en) * 2003-05-22 2005-07-14 Euan Ashley Diagnostic markers and pharmacological targets in heart failure and related reagents and methods of use thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FUJISAWA, H. ET AL.: "Expression of basic fibroblast growth factor and its receptor-1 in cardiac myxoma.", J. CARDIOVASC. SURG., vol. 43, 2002, pages 589 - 594, XP008118588 *
KARDAMI, E. ET AL.: "Regulation of basic fibroblast growth factor (bFGF) and FGF receptors in the heart.", ANN. N.Y. ACAD. SCI., vol. 752, 1995, pages 353 - 369, XP008118448 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8691587B2 (en) 2008-04-30 2014-04-08 Roche Diagnostics Operations, Inc. Use of SFRP-3 in the assessment of heart failure

Also Published As

Publication number Publication date
CA2580191A1 (en) 2006-03-30
EP1797199A2 (en) 2007-06-20
WO2006034356A9 (en) 2006-06-22
US20060094038A1 (en) 2006-05-04
WO2006034356A2 (en) 2006-03-30
JP2008515394A (en) 2008-05-15

Similar Documents

Publication Publication Date Title
WO2006034356A3 (en) Cardiac pressure overload associated genes
EP0904277A4 (en) Compositions and methods for the treatment and diagnosis of cardiovascular disease
WO2008008986A3 (en) Methods and reagents for treatment and diagnosis of vascular disorders and age-related macular degeneration
WO2004027033A3 (en) Lentiviral vector-mediated gene transfer and uses thereof
WO2006063704A3 (en) Single nucleotide polymorphism (snp) associated to type ii diabetes
WO2006065658A3 (en) A physiogenomic method for predicting clinical outcomes of treatments in patients
WO2002038794A3 (en) Cardiovascular disease diagnostic and therapeutic targets
WO2003031650A3 (en) Genes and proteins for prevention, prediction, prognosis and therapy of cardiovascular disease
WO2005067391A3 (en) Diagnostic test for parkinson's disease
Seidel et al. The differential impact of aerobic and isometric handgrip exercise on blood pressure variability and central aortic blood pressure
Gunes et al. Frequency of angiotensin‐converting enzyme gene polymorphism in Turkish hypertensive patients
WO2004026107A3 (en) Kits and methods for assessing skin health
NO20073636L (en) Compositions and Methods to Treat Mental Disorders
WO2005025409A3 (en) Methods for risk assessment, survival prediction and treatment of heart failure and other conditions based on adrenergic receptor polymorphisms
WO2005119260A3 (en) Methods for predicting and monitoring response to cancer therapy
WO2001081634A3 (en) Methods and compositions for the diagnosis and treatment of cardiovascular and tumorigenic disease using 4941
WO2009087689A3 (en) Novel primers for identification of astrocytoma, it's grades and glioblastoma prognosis
WO2006017573A3 (en) Method for the early detection of pancreatic cancer and other gastrointestinal disease conditions
WO2007006862A3 (en) Method and kit for detecting a risk of coronary heart disease
WO2004005886A3 (en) Kits and methods for assessing cardiovascular health
WO2005117941A3 (en) Methods and compositions for the treatment of polycystic diseases
WO2006063703A8 (en) Single nucleotide polymorphism (snp) associated to type ii diabetes
EP1992701A3 (en) Kits and methods for assessing oxidative stress
Sinha et al. Brief report: β-blocker use among veterans with systolic heart failure
Aronow What should the target blood pressure goals be?

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/17-17/17, DRAWINGS, REPLACED BY NEW PAGES 1/17-17/17; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2580191

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007532650

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005806752

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005806752

Country of ref document: EP